Chinese Biotech Firm Immunochina Raises $20M In Series C Round

Chinese biotechnology company Immunochina Pharmaceuticals has raised a RMB$140 million (US$20.4 million) series C round of financing led by a syndicate of Chinese and international investors, according to a statement released on January 22.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

China Expert network

LEAVE A REPLY